Raze Therapeutics

Name

Raze Therapeutics

Website

https://razetx.com

Company type

Private

Founded year

2013

Headcount range

1–10 employees

Ownership category

akta.pro rank

Product category

Oncology Therapeutics

NAICS

Research and Development in Biotechnology (except Nanobiotechnology) (541714), Scientific Research and Development Services (5417), Pharmaceutical Preparation Manufacturing (325412)

SIC

Pharmaceutical Preparations (2834), Biological Products, (No Disgnostic Substances) (2836)

akta.pro primary industry

Oncology Specialty Pharmaceuticals (HLAIACAA)

akta.pro secondary industries

Oncology & Hematology Pharmaceuticals (HLAIAAAC), Target Identification & Validation Platforms (omics-driven, chemoproteomics, genetic validation) (HLAAAIAI)

Keywords

• Oncology therapeutics
• Cancer drug discovery
• Biotechnology research
• Metabolism therapeutics
• Oncology drug development

Headquarters

HQ city

Cambridge

HQ country

United States

HQ region

North America

Markets served

GTM type

B2B

Offering type

Hardware or Manufacturing

Cost components

Technology or R&D, Personnel, Operations

Core offering

Raze Therapeutics, Inc. is a biotechnology company that engages in the discovery and development of oncology therapeutics. The company focuses on identifying and advancing novel therapeutic candidates targeting cancer, leveraging its scientific platform to develop treatments intended to address unmet needs in oncology.

Differentiator

Problem solved

Functional benefit

Products and services

• Oncology Therapeutics Pipeline

Ideal customer profiles2 records

Technology focussed Yes

API detail

Has API

No

API docs

API detail

Core technology

AI maturity

App detail

Broad incumbents

• Epizyme: Commercial-stage epigenetics oncology company with multiple programs. Comparable as a venture-backed oncology biotech that translated mechanism-driven science into partnered/commercial assets.
• Mirati Therapeutics: Targeted-oncology company developing small molecules against validated oncogenic drivers. Comparable as a venture-backed precision-oncology biotech that scaled to a multi-asset pipeline and strategic acquisition (BMS).

Direct peers

• Forma Therapeutics: Discovery-stage oncology biotech focused on metabolic and epigenetic targets in hematologic malignancies and solid tumors. Closely comparable business model and therapeutic-area focus.
• Calithera Biosciences: Clinical-stage biotech developing small molecules targeting tumor metabolism (glutaminase, arginase). Directly comparable as a discovery-stage-to-clinical cancer-metabolism company with overlapping target classes.
• Agios Pharmaceuticals: Pioneer in cancer-metabolism drug discovery (IDH inhibitors, mitapivat). Direct peer given Raze's founders' cancer-metabolism expertise and Agios's leadership in commercializing metabolism-targeted oncology and hematology therapies.
• Cornerstone Pharmaceuticals: Developer of cancer-metabolism-directed therapeutics (CPI-006 and related metabolic modulators). Niche peer in the same metabolic-oncology subcategory.

Others

• Atlas Venture: Lead investor in Raze's 2014 round and a leading early-stage biotech venture firm. Comparable as the institutional sponsor shaping Raze's company-building model and exit pathway.
• MPM Capital: Healthcare-dedicated venture firm and 2014 Raze investor. Comparable as an oncology-focused capital partner with a track record of building and exiting clinical-stage biotechs.

Emerging players

• Peloton Therapeutics: Discovery-stage oncology company targeting HIF-2α and related metabolic/hypoxia pathways. Comparable as a venture-backed, mechanism-driven oncology startup that was acquired by Merck.
• Constellation Pharmaceuticals: Clinical-stage epigenetics-focused oncology biotech. Comparable as a venture-backed targeted-oncology company that executed a strategic pharma exit (MorphoSys acquisition).

Market position

Customer concentration

• Xx.com/razetx
• LinkedInlinkedin.com/company/raze-therapeutics-inc-

Revenue estimate

Valuation estimate

Number of profiles

Profiles4 records

Funding overview

Funding rounds1 record

Investors6 records

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about Raze Therapeutics